Dana-Farber Cancer Institute Company Research Report
Company Overview
- Name: Dana-Farber Cancer Institute
- Mission: Defeating cancer is the sole mission of Dana-Farber Cancer Institute. It focuses on providing the most advanced cancer care available while conducting research to develop tomorrow’s breakthrough therapies.
- Founded: Established in 1947 by Sidney Farber, MD.
- Key People:
- Daniel J. DeAngelo, MD, PhD: Chief of the Division of Leukemia.
- Jennifer R. Brown, MD, PhD: Investigator and trial leader.
- Colleen A. Kelly, MD: Pediatric hematology/oncology fellow.
- Kira Bona, MD, MPH: Pediatric oncologist.
- Ursula A. Matulonis, MD: Chief of the Division of Gynecologic Oncology.
- Otto Metzger, MD: Medical oncologist, Dana-Farber Cancer Institute.
- Matthew S. Davids, MD, MMSc: Clinical Research Director, Division of Lymphoma.
- Ann H. Partridge, MD, MPH: Interim Chair of Medical Oncology.
- Headquarters: 450 Brookline Avenue, Boston, MA 02215
- Number of Employees: Over 5,000 including staff, faculty, and clinicians.
- Revenue: No information is available.
- Known For: Known for leading cancer research and providing groundbreaking therapies. It's recognized for contributions in developing FDA-approved cancer drugs.
Products
- Products Offered:
- Dana-Farber offers cutting-edge cancer treatments and research opportunities. No specific product names are available.
- High-Level Description & Key Features:
- Cancer Treatments: Dana-Farber is renowned for its specialized approach to cancer care, including personalized treatment plans for different types of cancers.
- Research Initiatives: They focus on cancer research to bring new therapies from bench to bedside and are involved in numerous clinical trials to evaluate new treatments.
Recent Developments
- New Products or Therapies Launched:
- Triplet Therapy for CLL: A novel triplet therapy comprising acalabrutinib, venetoclax, and obinutuzumab shows promise in chronic lymphocytic leukemia (CLL).
- CDK 4/6 Inhibitor: The addition of this compound has shown significant benefits in patients with metastatic breast cancer.
- New Features or Advancements:
- Predictive Mathematical Models: Introduction of a novel model to improve diagnosis and treatment strategies in systemic mastocytosis.
- New Drug Combinations: Advancements in drug combinations for various cancer treatments, such as AML and CLL, have been presented at recent symposiums and conferences.
- Partnerships and Collaborations:
- Dana-Farber collaborates with Brigham and Women's Hospital and Boston Children's Hospital. They are a teaching affiliate of Harvard Medical School and part of the Dana-Farber/Harvard Cancer Center.
- Research Projects and Studies:
- Numerous studies presented at conferences such as ASH highlight Dana-Farber's relentless pursuit of advancements in cancer treatment, including insights into AML, breast cancer, and more.
Dana-Farber Cancer Institute stands as a cornerstone of cancer care and research, continuously pushing the boundaries of what is possible in the treatment and understanding of cancer globally.
